Medication info
Telostop Tablet 40/5 mg

Telostop Tablet 40/5 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Ildong Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
30 tablets/box [(10 tablets/Alu-Alu) x 3], 30 tablets/bottle
Approval status
Active

MFDS item code 201505196 · Approved 2015.07.31 · Insurance code 642905520

Summary

Main use
Treatment of essential hypertension, improvement of dyslipidemia, inhibition of atherosclerosis, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased up to 80 mg once daily. When this medicine is administered concomitantly with a thiazide diuretic such as hydrochlorothiazide, an additional blood pressure-lowering effect is produced. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after initiation of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine for cardiovascular risk reduction, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild to moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of the day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response; the dose may be increased up to a maximum of 20 mg once daily. 2. Older adults: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, whereas an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience.

Ingredients

Manufacturer
Ildong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension, improvement of dyslipidemia, inhibition of atherosclerosis, and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • abnormal beta-lipoproteinemia
View approved original text

This medicine is used for patients who need to take Telmisartan and Rosuvastatin simultaneously. Telmisartan is primarily used to help control blood pressure in patients with essential hypertension and to reduce the risk of cardiovascular disease. It particularly reduces the risk of myocardial infarction, stroke, and death due to cardiovascular disease in high-risk patients who cannot use ACE inhibitors or have a history of coronary artery disease, peripheral artery disease, or stroke. Rosuvastatin is used when dietary management and exercise are insufficient in patients with hypercholesterolemia and hyperlipidemia, lowering total cholesterol and LDL cholesterol levels to delay the progression of atherosclerosis. Additionally, Rosuvastatin helps reduce the risk of stroke, myocardial infarction, and vascular re-intervention in elderly patients with cardiovascular risk factors. Therefore, this medicine effectively improves the risk of cardiovascular disease through blood pressure and cholesterol management.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased up to 80 mg once daily. When this medicine is administered concomitantly with a thiazide diuretic such as hydrochlorothiazide, an additional blood pressure-lowering effect is produced. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after initiation of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine for cardiovascular risk reduction, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild to moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of the day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response; the dose may be increased up to a maximum of 20 mg once daily. 2. Older adults: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, whereas an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience.

Precautions

This drug can cause serious harm to the fetus and newborn if used during pregnancy, particularly in the second and third trimesters, so it must be discontinued immediately upon confirmation of pregnancy. People who are allergic to this drug or its ingredients, women who are pregnant or may become pregnant, and nursing women should avoid taking this medication. Patients with severely impaired liver or kidney function, those with specific liver diseases or muscle disorders, and those taking certain medications should not use this drug or should use it with great caution. Elderly patients or patients with hyperkalemia, liver or kidney problems, or cardiovascular diseases should also exercise caution when taking this drug. This drug may cause muscle-related side effects such as muscle pain or weakness, so patients should consult a doctor immediately if any muscle-related symptoms occur. Additionally, various side effects such as liver dysfunction, allergic reactions, low blood pressure, and decreased kidney function may occur, necessitating regular examinations. There may be drug interactions, so if you are taking other medications, it is essential to inform your doctor or pharmacist. Dizziness or drowsiness may occur while driving or operating machinery, so caution is advised. Safety and efficacy in children have not been established, so it is not recommended for use. In cases of overdose, symptoms such as low blood pressure, dizziness, and acute renal failure may occur, necessitating immediate medical attention. This medication should be stored out of reach of children, and it should not be transferred to other containers.

Side effects

Headache, positional dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, elevated ALT, dysuria, rhinitis, pharyngeal discomfort, pulmonary diseases, gastrointestinal diseases, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory tract infections, urinary tract infections, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reactions, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal bloating, vomiting, abdominal discomfort, dry mouth, liver dysfunction, liver disorders, increased sweating, pruritus, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin, hypoglycemia, angioedema, hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, headache, facial spasms, sensory abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, appetite loss, arrhythmia, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, palpitations, fatigue, nausea, lack of effect, cough, dyspepsia, palpitations, myalgia, elevated CK, constipation, increased AST, weakness, arthralgia, fatigue, numbness, sensory abnormalities, discomfort in the chest, nausea, abdominal pain, diarrhea, appetite loss, abdominal bloating, itching, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, arrhythmia, thrombocytopenia, increased serum creatinine, acute renal failure, oliguria

Not everyone experiences these, and they can vary from person to person.

Storage

This drug may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is best to maintain storage temperatures between 1 and 30 degrees Celsius to safely preserve the effectiveness of the medication.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

30 tablets/box [(10 tablets/Alu-Alu) x 3], 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.